Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04255875 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

A Phase 1 study of Healthy and Sickle Cell Anemia, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
52
Enrollment target
16
Study locations

NCT04255875 is a Phase 1 study of Healthy and Sickle Cell Anemia that has completed, run by Pfizer. The registered enrollment target is 52 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04255875, a Phase 1 study of Healthy and Sickle Cell Anemia, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
52 participants
Enrollment target
16
Study locations

Study Summary

This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in healthy participants and participants with sickle cell disease.

Conditions Studied

Healthy Sickle Cell Anemia

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL PF-07209326

Study Locations (16)

Florida

  • Golisano Children's Hospital of Southwest Florida - Fort Myers
  • Lee Health - Golisano Children's Hospital of Southwest Florida - Fort Myers
  • Foundation for Sickle Cell Disease Research - Hollywood
  • Foundation for Sickle Cell Disease Research - Hollywood

New York

  • Columbia University Medical Center - Herbert Irving Pavilion - New York
  • CUIMC Research Pharmacy - New York
  • CUMC Research Pharmacy - New York

Texas

  • UT Physicians Comprehensive Sickle Cell Center Houston - Houston
  • Memorial Hermann clinical research unit - Houston
  • UT Physicians Comprehensive Sickle Cell Center Houston - Houston

Illinois

  • University of Illinois at Chicago Clinical Research Center - Chicago
  • University of Illinois at Chicago - Chicago

Connecticut

  • New Haven Clinical Research Unit - New Haven

District of Columbia

  • Howard University College of Medicine - Washington D.C.

Georgia

  • Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center - Atlanta

Minnesota

  • Prism Research LLC dba Nucleus Network - Saint Paul

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2020-02-05
Est. Completion 2023-07-07
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04255875

The ClinicalTrials.gov registry entry for NCT04255875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04255875 reports 16 study locations spanning 8 distinct geographic areas - top geographies include Florida, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT04255875 about?

NCT04255875 is a clinical study titled "Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease". This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in healthy participants and participants with sickle cell disease.

What is the current status of trial NCT04255875?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2020-02-05. Estimated completion is 2023-07-07.

What conditions does trial NCT04255875 study?

This clinical trial studies the following conditions: Healthy, Sickle Cell Anemia.

What interventions are being tested in trial NCT04255875?

The interventions under investigation include: Placebo (BIOLOGICAL), PF-07209326 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04255875?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04255875 being conducted?

This trial has 16 study locations across Connecticut, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Sickle Cell Anemia

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.